Oxi 4503

07/06/2020 - "We observed no significant improvement with lower OXi4503 doses (5-25 mg/kg) and anti-CTLA-4, although 30% of tumors were controlled at the 25 mg/kg dose. "
07/01/2008 - "Intermittent dosing with Oxi4503 produced the maximum reduction in tumor growth, minimal toxicity, and a significant improvement in survival. "
05/01/2012 - "The system was also used to study the temporal evolution of the response of the tumor vasculature following the administration of a therapeutic vascular disrupting agent (OXi4503). "
01/01/2008 - "This study evaluates the pattern of microcirculatory changes and alterations to the ultrastructural properties of the tumor vasculature that result from OXi4503 treatment. "
07/01/2006 - "The present studies show that the second-generation VDA OXi4503 possesses significant antivascular effects in solid tumors. "

11/01/2015 - "Moreover, the ongoing clinical trial of OXi4503 (combretastatin-A1 diphosphate) together with preliminary preclinical evaluation for the treatment of refractory acute myelogenous leukemia has successfully highlighted both the indirect and direct anticancer properties of combretastatins. "
12/26/2019 - "Combretastatin A1 (OXi4503) is a dual-function drug with vascular disrupting and cytotoxic properties that has exhibited single-agent anti-leukemia activity in murine xenograft models of acute myeloid leukemia (AML) and in a prior Phase 1A clinical study for relapsed/refractory (R/R) AML. "
01/01/2020 - "Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes."
12/26/2019 - "A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia."

01/01/2020 - "Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes."

07/01/2008 - "This study investigates the effect of Oxi4503 on colorectal liver metastases in a murine model. "
10/01/2013 - "In this study we demonstrated an immediate and widespread EMT involving all surviving tumor cells following treatment of a mouse model of colorectal liver metastases with the vascular disruptive agent OXi4503. "
11/15/2012 - "The molecular and morphological differences between tumor periphery and center may account for the observed differential resistance to OXi4503 treatment and could provide targets for drug development to totally eliminate metastases."
11/15/2012 - "Using a murine colorectal liver metastases model, spatial morphological and molecular differences within the periphery and the center of the tumor that may account for differences in resistance to OXi4503 treatment were investigated. "
07/01/2008 - "A single dose of Oxi4503 produced significant necrosis and microvascular injury in colorectal liver metastases. "

03/01/2009 - "A single dose of OXi4503/CA1P caused complete shutdown of vasculature by 24h and extensive haemorrhagic necrosis by 48h. "
01/01/2011 - "The results showed that the cis-isomer (OXi4503) significantly impaired tumor blood flow leading to secondary tumor cell death and >95% tumor necrosis 24h post drug exposure. "
07/01/2008 - "A single dose of Oxi4503 produced significant necrosis and microvascular injury in colorectal liver metastases. "
07/01/2008 - "A single dose of 5 or 50 mg/kg of Oxi4503 produced significant tumor necrosis compared to the controls. "
07/01/2007 - "A single dose of Oxi4503 caused immediate tumor vasculature collapse and subsequently tumor necrosis. "